Can we use adenosine diphosphate (ADP) to study "aspirin resistance" The Janus faces of ADP-triggered platelet aggregation

Pharmacological Reports

Volumn 60, Issue 3, 2008, Pages 361-368

  Dobaczewski, Marcin ^a,d   Golański, Jacek ^a   Kowalski, Tomasz ^a   Nocuń, Marek ^a   Rózalski, Marcin ^a   Kostka, Barbara ^b   Ulicna, Olga ^c   Mussur, Miroslaw ^a   Markuszewski, Leszek ^a   Watała, Cezary ^a  

^a MEDICAL UNIVERSITY OF LODZ   (Poland)

^b UNIVERSITY OF LODZ   (Poland)

^c Physics and Informatics   (Slovakia)

^d INTERNATIONAL INSTITUTE OF MOLECULAR AND CELL BIOLOGY   (Poland)

Author keywords

Acetylsalicylic acid; Platelet aggregation inhibitors; Rats; TXA2 generation

Indexed keywords

ACETYLSALICYLIC ACID; ADENOSINE DIPHOSPHATE; ARACHIDONIC ACID; HIRUDIN; LYSINE ACETYLSALICYLATE; THROMBOXANE A2;

ANIMAL CELL; ANIMAL EXPERIMENT; ANTICOAGULATION; ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DOSAGE SCHEDULE COMPARISON; DRUG BLOOD LEVEL; DRUG MECHANISM; DRUG MONITORING; EX VIVO STUDY; IN VITRO STUDY; MALE; NONHUMAN; RAT; SINGLE DRUG DOSE; THROMBOCYTE AGGREGATION; THROMBOCYTE AGGREGATION INHIBITION;

EID: 49349116529     PISSN: 22995684     EISSN: 22995684     Source Type: Journal    
DOI: None     Document Type: Article

References (36)

1. Aguejouf O, Belougne-Malfatti E, Doutremepuich F, Belon P, Doutremepuich C: Thromboembolic complications several days after a single-dose administration of aspirin. Thromb Res, 1998, 89, 123-127.
2. Baugh RF: Platelets and whole blood coagulation. Perfusion, 2000, 15, 41-50.
3. Bhatt DL: Aspirin resistance: more than just a laboratory curiosity. J Am Coll Cardiol, 2004, 43, 1127-1129.
4. Boncler M, Gresner P, Nocun M, Rywaniak J, Dolnik M, Rysz J, Wil R et al.: Elevated cholesterol reduces acetylsalicylic acid-mediated platelet acetylation. Biochim Biophys Acta, 2007, doi:10.1016/ j.bbagen.2007.09.002.
5. Cardinal DC, Flower RJ: The electronic aggregometer: a novel device for assessing platelet behavior in blood. J Pharmacol Methods, 1980, 3, 135-158.
6. Cazenave JP, Gachet C: Anti-platelet drugs: Do they affect megakaryocytes? Bailliere Clin Haematol, 1997, 10, 163-180.
7. Doutremepuich C, de Seze O, Le Roy D, Lalanne MC, Anne MC: Aspirin at very ultra low dosage in healthy volunteers: effects on bleeding time, platelet aggregation and coagulation. Haemostasis, 1990, 20, 99-105.
8. Fritsma GA, Ens GE, Alvord MA, Carroll AA, Jensen R: Monitoring the antiplatelet action of aspirin. JAAPA, 2001, 14, 57-62.
9. Gachet C, Hechler B, Leon C, Vial C, Leray C, Ohlmann P, Cazenave JP: Activation of ADP receptors and platelet function. Thromb Haemost, 1997, 78, 271-275.
10. George JN: Platelets. Lancet, 2000, 355, 1531-1539.
11. Golański J, Nocuń M, Rózalski M, Drygas W, Watala C: An in vitro model for the detection of reduced platelet sensitivity to acetylsalicylic acid. Blood Coagul Fibrinolysis, 2004, 15, 1-9.
12. Gum PA, Kottke-Marchant K, Poggio ED, Gurm H, Welsh PA, Brooks L, Sapp SK et al.: Profile and prevalence of aspirin resistance in patients with cardiovascular disease. Am J Cardiol, 2001, 88, 230-235.
13. IIbβ3 and ADP receptors. Blood, 2002, 99, 193-198.
14. Lev EI, Patel RT, Maresh KJ, Guthikonda S, Granada J, DeLao T, Bray PF et al.: Aspirin and clopidogrel, drug response in patients undergoing percutaneous coronary intervention: the role of dual drug resistance. J Am Coll Cardiol, 2006, 47, 27-33.
15. Lordkipanidze M, Pharand C, Schampaert E, Turgeon J, Palisaitis DA, Diodati JG: A comparison of six major platelet function tests to determine the prevalence of aspirin resistance in patients with stable coronary artery disease. Eur Heart J, 2007, 28, 1702-1708.
16. Macchi L, Christiaens L, Brabant S, Sorel N, Allal J, Mauco G, Brizard A: Resistance to aspirin in vitro is associated with increased platelet sensitivity to adenosine diphosphate. Thromb Res, 2002, 107, 45-49.
17. Mattiasson I, Lethagen S, Hillarp A: Increased sensitivity to ADP-aggregation in aspirin treated patients with recurrent ischemic stroke? Int Angiol, 2003, 22, 239-242.
18. McCabe DJ, Harrison P, Mackie U, Sidhu PS, Lawrie AS, Purdy G, Machin SJ et al.: Assessment of the anti-platelet effects of low to medium dose aspirin in the early and late phases after ischaemic stroke and TIA. Platelets, 2005, 16, 269-280.
19. Murugappan S, Shankar H, Kunapuli SP: Platelet receptors for adenine nucleotides and thromboxane A2. Semin Thromb Hemost, 2004, 30, 411-418.
20. Mustard JF, Perry DW, Ardline NC, Packham MA: Preparation of suspension of washed platelets from humans. Br J Haematol, 1977, 22, 193.
21. Nocuń M, Golański J, Lapshina E, Zavodnik L, Dohaczewski M, Kazmierczak P, Markuszewski L et al.: Usefulness of whole blood aggregometry and its comparison with thromboxane generation assay in monitoring acetylsalicylic acid effectiveness - a multiparametric study in rats. Clin Chem Lab Med, 2006, 44, 853-862.
22. Ohmori T, Yatomi Y, Nonaka T, Kobayashi Y, Madoiwa S, Mimuro J, Dzaki Y et al.: Aspirin resistance detected with aggregometry cannot be explained by cyclooxygenase activity: involvement of other signaling pathway(s) in cardiovascular events of aspirin-treated patients. J Thromb Haemost, 2006, 4, 1271-1278.
23. 2- in the suspending medium on the responses of human and rabbit platelets to aggregating agents. Thromb Haemost, 1989, 62, 968-976.
24. Patrono C, Coller B, FitzGerald GA, Hirsh J, Roth G: Platelet-active drugs: the relationships among dose, effectiveness, and side effects: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest, 2004, 126, 234S-264S.
25. 2a, receptors. J Biol Chem, 1999, 274, 29108-29114.
26. Pulcinelli FM, Pignatelli P, Celestini A, Riondino S, Gazzaniga PP, Violi F: Inhibition of platelet aggregation by aspirin progressively decreases in long-term treated patients. J Am Coll Cardiol, 2004, 43, 979-984.
27. Puri RN, Colman RW: ADP-induced platelet activation. Crit Rev Biochem Mol Biol, 1997, 32, 437-502.
28. Samuelsson B, Goldyne M, Granstrom E, Hamberg M, Hammarstrom S, Malmsten C: Prostaglandins and thromboxanes. Annu Rev Biochem, 1978, 47, 997-1029.
29. Schror K: Aspirin and platelets: the antipletelet action of aspirin and its role in thrombosis treatment and prophylaxis. Semin Thromb Hemost, 1997, 23, 349-356.
30. 2 integrins in hemostasis and vascular biology. Tbromb Haemost, 1995, 74, 149-155.
31. Soloviev MV, Okazaki Y, Harasaki H: Whole blood platelet aggregation in humans and animals: a comparative study. J Surg Res, 1999, 82, 180-187.
32. Szczeklik A, Musiał J, Undas A, Sanak M, Nizankowski R: Aspirin resistance. Pharmacol Rep, 2005, 57, Suppl, 33-41.
33. Tohti I, Tursun M, Umar A, Turdi S, Imin H, Moore N: Aqueous extracts of Ocimum basilicum L. (sweet basil) decrease platelet aggregation induced by ADP and thrombin in vitro and rats arterio-venous shunt thrombosis in vivo. Thromb Res, 2006, 118, 733-739.
34. Toth O, Calatzis A, Penz S, Losonczy H, Siess W: Multiple electrode aggregometry: a new device to measure platelet aggregation in whole blood. Thromb Haemost, 2006, 96, 781-788.
35. Vanderloo B, Martin JF: Megakaryocytes and platelets in vascular disease. Bailliere Clin Haematol, 1997, 10, 109-123.
36. Williams MS, Kickler TS, Vaidya D, Ng'alla LS, Bush DE: Evaluation of platelet function in aspirin treated patients with CAD. J Thromb Thrombolysis, 2006, 21, 241-247.